|Articles|February 19, 2014
LCGC TV: Koen Sandra on Analyzing Protein Biopharmaceuticals Using LC–MS
By 2020, more than 50% of approved drugs are expected to be protein biopharmaceuticals. Koen Sandra from the Research Institute for Chromatography in Belgium discusses the challenges of characterizing protein biopharmaceuticals and why LC–MS is now indispensable for characterizing this class of drugs.
Advertisement
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
